{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.953"},{"groupId":"OG001","value":"0.883"}]}],"title":"Proportion achieving target in ≤4 days"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.047"},{"groupId":"OG001","value":"0.117"}]}],"title":"Proportion not achieving target in ≤4 days"}],"denoms":[{"counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"154"}],"units":"Participants"}],"description":"Proportion of participants achieving a target of ≥ 2\\*10\\^6 CD34+ cells/kg in 4 or fewer days of apheresis. Central lab data were taken from Days 5 to 8 of the Treatment/Apheresis period. Each participant's value was calculated as the sum of all daily values collected over the 4 apheresis days.","groups":[{"description":"Participants underwent mobilization with G-CSF for 4 days. On the evening of Day 4, participants received a dose of plerixafor. On each subsequent day, participants received a morning dose of G-CSF followed by apheresis and an evening dose of plerixafor for a maximum of 4 aphereses or until ≥ 6\\*10\\^6 CD34+ cells/kg were collected.","id":"OG000","title":"G-CSF Plus Plerixafor"},{"description":"Participants underwent mobilization with G-CSF for 4 days. On the evening of Day 4, participants received a dose of placebo. On each subsequent day, participants received a morning dose of G-CSF followed by apheresis and an evening dose of placebo for a maximum of 4 aphereses or until ≥ 6\\*10\\^6 CD34+ cells/kg were collected.","id":"OG001","title":"G-CSF Plus Placebo"}],"paramType":"NUMBER","populationDescription":"Intent-to-Treat Population","reportingStatus":"POSTED","timeFrame":"up to Day 8","title":"Proportion of Participants Achieving a Target of ≥ 2*10^6 CD34+ Cells/kg in 4 or Fewer Days of Apheresis.","type":"SECONDARY","unitOfMeasure":"proportion of participants"}